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ABSTRACT
Objectives: To investigate the cost-effectiveness of a
chronic obstructive pulmonary disease (COPD) disease
management (COPD-DM) programme in primary care,
called RECODE, compared to usual care.
Design: A 2-year cluster-randomised controlled trial.
Setting: 40 general practices in the western part of
the Netherlands.
Participants: 1086 patients with COPD according to
GOLD (Global Initiative for COPD) criteria. Exclusion
criteria were terminal illness, cognitive impairment,
alcohol or drug misuse and inability to fill in Dutch
questionnaires. Practices were included if they were
willing to create a multidisciplinary COPD team.
Interventions: A multidisciplinary team of caregivers
was trained in motivational interviewing, setting up
individual care plans, exacerbation management,
implementing clinical guidelines and redesigning the
care process. In addition, clinical decision-making was
supported by feedback reports provided by an ICT
programme.
Main outcome measures: We investigated the
impact on health outcomes (quality-adjusted life years
(QALYs), Clinical COPD Questionnaire, St. George’s
Respiratory Questionnaire and exacerbations) and costs
(healthcare and societal perspective).
Results: The intervention costs were €324 per patient.
Excluding these costs, the intervention group had €584
(95% CI €86 to €1046) higher healthcare costs than
did the usual care group and €645 (95% CI €28 to
€1190) higher costs from the societal perspective.
Health outcomes were similar in both groups, except
for 0.04 (95% CI −0.07 to −0.01) less QALYs in the
intervention group.
Conclusions: This integrated care programme for
patients with COPD that mainly included professionally
directed interventions was not cost-effective in primary
care.
Trial registration number: Netherlands Trial
Register NTR2268.
INTRODUCTION
Disease management programmes for
chronic obstructive pulmonary disease
(hereafter referred to as COPD-DM) have
been developed to change COPD care from
acute, reactive and one-size-fits-all into inte-
grated, proactive and tailor-made. To stimu-
late the implementation of such programmes
in the Netherlands, a new payment policy
(ie, bundled payment) was recently imple-
mented.1 However, the wide implementation
of these programmes in the Netherlands, as
is currently ongoing, would benefit by a justi-
fication from a cost-effectiveness perspective.
Recent systematic literature reviews of
COPD-DM programmes showed favourable
effects on both health outcomes and costs
(mainly due to decreased hospitalisation).2 3
However, previous economic studies had
poor methodological quality.2 4 Most studies
did not measure all relevant costs and health
outcomes and did not perform incremental
cost-effectiveness analyses.2 For instance,
there is little knowledge on the required
investments in implementation of these pro-
grammes. Furthermore, the generalisability
of the outcomes of these studies was low, due
Strengths and limitations of this study
▪ It is the largest and most pragmatic Dutch
randomised controlled trial to date assessing the
cost-effectiveness of a disease management pro-
gramme for chronic obstructive pulmonary
disease patients in primary care.
▪ The 2-year follow-up period, the broad range of
health outcomes and costs (including pro-
gramme costs) measured and the statistically
sophisticated analyses ensure the robustness of
the results.
▪ The uncertainty in the cost-effectiveness of the
disease management programmes is adequately
estimated and illustrated, enabling the appropri-
ate interpretation of the results.
▪ The control group was likely to be exposed to
quality improvement initiatives as part of usual
care.
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to the inclusion of patients with mainly severe COPD
and the exclusion of patients with multimorbidity.2 5 6
We aimed to conduct a comprehensive cost-
effectiveness analysis (CEA) of a COPD-DM programme
in primary care compared to usual care in the
Netherlands. This CEA was performed as part of a 2-year
cluster randomised controlled trial (RCT) evaluating the
clinical effects of this RECODE programme (acronym
for Randomised clinical trial on Effectiveness of inte-
grated COPD management in primary carE).7 8
In the clinical paper we concluded that, after
12 months, the RECODE programme did not signifi-
cantly improve the score on the Clinical COPD
Questionnaire (CCQ) compared to usual care, despite
an improved level of integrated care and a higher
degree of self-reported physical activity.7 Our current
paper includes additional outcome measures not
reported in the clinical paper and it reports 24-month
results. This is important because it is often argued that
it takes time before the effect of DM programmes
becomes clearly visible. The added value of a cost-
effectiveness analysis is that we report the joint uncer-
tainty in effects and costs, allowing us to report the prob-
ability that the RECODE programme would be
cost-effective at various threshold values of the
maximum acceptable costs per quality-adjusted life year
(QALY) gained. Moreover, the publication of results in
terms of cost-effectiveness is important to avoid selective
reporting of positive studies. The published evidence is
used to inform all decisionmakers across developed
countries about whether and which COPD-DM pro-
grammes to reimburse on a wider scale.
METHODS
This study was approved by the medical ethics commit-
tee, performed according to the study protocol,8 as well
as national9 and international10 guidelines for pharma-
coeconomic research, and reported according to the
Consolidated Health Economic Evaluation Reporting
Standard (CHEERS).11
Design and intervention
RECODE is a 2-year cluster randomised trial in which 40
clusters of primary care teams were randomised to the
COPD-DM programme or usual care. The 20 teams of
the intervention group were trained in essential compo-
nents of effective COPD-DM: proper diagnosis, optimis-
ing medication adherence, motivational interviewing,
smoking cessation counselling, applying self-
management plans including early recognition and
treatment of exacerbations, physical (re)activation and
nutritional support. In addition, the teams learnt the
details of a web-based computer program for measuring
and reporting process and outcome performance indica-
tors, named ZORGDRAAD. This Information and
Communications Technologies (ICT) application
included a patient and provider portal that facilitated
the communication within the multidisciplinary teams
as well as between care providers and patients. At the
end of the 2-day course, each team developed a plan
with steps to be taken in order to redesign the care
process and integrate the COPD-DM programme into
their daily practice. After the course, the teams were
invited to join refresher courses, received regular feed-
back reports on patients’ outcomes and had access to
ZORGDRAAD. The local healthcare insurer reimbursed
physical reactivation for patients with a Medical
Research Council (MRC) dyspnoea score >2, and also if
these patients had no supplementary insurance. All prac-
tices were flexible in determining and following their
individual plans. Therefore, the mix and intensity of
interventions for individual patients depended on their
health status, personal needs and preferences, as well as
the actions taken by the team. Healthcare providers in
the usual care group were asked to continue providing
care as usual. The care as usual has been reported
previously.8
Target population
The enrolment of primary care teams and their
patients with COPD took place between September
2010 and September 2011. Participating teams included
at least one general practitioner (GP), one practice
nurse and one physiotherapist. Patients had physician-
diagnosed COPD according to GOLD guidelines.12
Exclusion criteria were terminal illnesses, dementia,
cognitive impairment, inability to complete question-
naires in Dutch and hard drug or alcohol abuse. Other
comorbidity was not an exclusion criterion. The GPs
verified that the included patients fulfilled the inclusion
and exclusion criteria. All participating GPs and
patients with COPD provided written informed consent
before participation.
Outcomes
Costs were related to the following outcome measures:
1. QALYs based on the EuroQol-5D (EQ-5D) utility
values using the Dutch value set;13 14
2. Proportion of patients with a minimal clinical import-
ant difference(MCID) (ie, improvement ≥0.4) on the
CCQ;15 16
3. Proportion of patients with an MCID (ie, improve-
ment ≥4) on St. George’s Respiratory Questionnaire
(SGRQ);17 18
4. Total number of COPD exacerbations (moderate and
severe). A moderate exacerbation was defined as a
worsening of daily symptoms that led a patient’s clin-
ician to prescribe systemic corticosteroids and/or
antibiotics, but did not require hospitalisation. This
information was extracted from the Electronic
Medical Records (EMR). A severe exacerbation was
defined as a worsening of symptoms that required a
hospital admission. Hospital admissions were
obtained from the resource use questionnaires and
the EMR.
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The EQ-5D, CCQ, SGRQ and resource use question-
naires were administered at baseline and at 6, 9, 12, 18
and 24 months.
Costs
Total 2-year costs (not only those related to COPD) were
calculated from a healthcare perspective and a societal
perspective. The healthcare perspective included all
costs covered by the healthcare budget, that is, medica-
tion prescriptions, contact with care providers (GP,
medical specialist, nurse, physiotherapist, dietician,
podiatrist, occupational therapist), home care, hospital
admissions, emergency department visits and pulmonary
rehabilitation. The costs from the societal perspective
additionally included travel costs and costs of productiv-
ity loss due to absence from paid work.
Patients reported the healthcare utilisation (excluding
medication), travel costs, days of absence from paid
work due to illness (absenteeism) and lost productivity
while being at work (presenteeism) in a resource use
questionnaire with a recall period of 3 months.
The medication prescriptions were extracted from the
EMRs of the GPs. Standard unit costs were obtained
from the Dutch manual for costing research9 and
inflated to 2013 using the general consumer price
index.19 The costs of medications were obtained from
the GIP-Databank and included value added tax and
pharmacist dispensing fees.20 The productivity costs
were estimated using the Friction Cost Approach, which
assumes that productivity loss occurs as long as a sick
employee is not replaced (the friction period).21 We
used a friction period of 115 days, that is, the average
duration of vacancies (87 days) increased with the
expected number of weeks employers need before
taking the decision to place a vacancy for temporary or
permanent replacement of the worker (28 days).22
The intervention costs, defined as costs of training the
teams, costs of the ICT support and costs of the monitor-
ing reports, were calculated on the basis of course
attendance (initial 2-day course and refresher courses),
computer-documented ICT-use and time involved in
producing monitoring reports (for each practice, the
estimated labour time was 2.5, 0.5 and 1 h to produce
the reports at baseline and at 6 months and 12 months,
respectively).
Statistical analysis
Data analysis was performed according to the
intention-to-treat principle. Data from patients who dis-
continued the trial prematurely were included in the
analysis up to the point of dropout. Additionally, patients
who dropped out during the first year were asked to fill
in a CCQ questionnaire at 12 months, if possible.
We used repeated measures models to assess differ-
ences between RECODE and usual care, correcting for
time, age, gender, MRC dyspnoea score >2, baseline
score and clustering of patients. The distribution and
link function for each outcome was selected after
comparing the goodness-of-fit of models with different
specifications of the distribution and link functions.
Models that had the lowest Akaike’s Information
Criterion were selected.
EQ-5D utilities were analysed using linear mixed
models with a normal distribution and identity link. We
calculated the number of QALYs for each patient as the
area under the predicted utility curve, using linear inter-
polation between two utility measurements. Generalised
linear mixed models with a binary distribution and logit
link were used to analyse the proportion of patients with
an MCID on the CCQ and SGRQ questionnaires. The
differences in exacerbation rates were estimated using
generalised linear mixed models with negative binomial
distribution and log link. Costs were analysed with gener-
alised linear mixed models using a log-normal distribu-
tion and identity link. The cost estimate for months 3–6
(based on the questionnaire administered in month 6)
was linearly extrapolated to include months 0–3.23
The same was carried out for the cost estimate of
months 15–18 and 21–24.
Cost-effectiveness
Cost-effectiveness was reported in terms of costs per
QALY. Additionally, the following incremental cost-
effectiveness ratios (ICERs) were calculated: costs per
additional patient with an MCID on the CCQ, costs per
additional patient with an MCID on the SGRQ and costs
per exacerbation prevented. Taking a multioutcome
approach is in line with recent guidelines.24
Uncertainty around the ICERs was handled by boot-
strapping the data 5000 times. Bootstrapping means
repeatedly drawing samples with replacement from the
original data set.25 Each sample has the same size as the
trial and for each sample the difference in costs and
QALYs between RECODE and usual care and the ICER
is calculated. The 2,5th and the 97,5th centile of the
5000 bootstrap replications form the 95% uncertainty
interval of the differences in costs and QALYs. The 5000
ICERs were plotted on cost-effectiveness planes.26 In a
cost-effectiveness plane, the horizontal axis displays the
difference in effects and the vertical axis displays the dif-
ference in costs. The results of the bootstrap replications
can fall into one of four quadrants: north-east quadrant
(more cost and more effects); south-east quadrant (less
cost and more effects); south-west quadrant (less cost
and less effects); north-west quadrant (more cost and
less effects; see online supplementary appendix 1).
Finally, the probability that the RECODE programme is
cost-effective using different thresholds for the monetary
value of a QALY was shown in cost-effectiveness accept-
ability curves.27 This probability equals the proportion of
bootstrap replications in which the ICER is lower than
the threshold value.
Sensitivity and subgroup analyses
Two sensitivity analyses were performed: one with the
inclusion of intervention costs and the other with a
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1-year instead of a 2-year time horizon. Five subgroup
analyses were performed to study the influence of age,
sex, dyspnoea, lung function and socioeconomic status.
These were all prespecified in the study protocol and
the power calculation was based on the subgroup ana-
lyses by MRC dyspnoea score >2.8
RESULTS
Patients
The flow chart of patient inclusion has been presented
elsewhere.7 In total, we included 1086 patients with
COPD from 40 teams in the trial, 554 in the RECODE
group and 532 in the usual care group. The baseline
characteristics of the patients in the RECODE and usual
care groups are summarised in table 1. The only statistic-
ally significant difference was a higher percentage of
males in the usual care group (51 vs 57%).
The proportion of patients who completed the trial
was 76% in the RECODE group and 74% in the usual
care group. Length of follow-up among the dropouts
was not significantly different between groups, with a
mean (±sd) follow-up of 20.5 (±0.29) and 20.0 (±0.33)
months, respectively. Patients who dropped out were sig-
nificantly older and had a significantly worse baseline
score on the CCQ, SGRQ, MRC-dyspnoea and EQ-5D.
Baseline characteristics between the dropouts of the
RECODE group and the usual care group were not sig-
nificantly different.
Costs
The intervention costs are presented in table 2. The
total intervention costs per patient ranged from €103 to
€587 across clusters, with a mean (±sd) of €324 (±156)
per patient. This variation is explained by the number of
patients with COPD per team, the use of the ICT system,
the number of healthcare providers participating in the
courses and the different locations of the courses. The
labour costs of the attendees of the RECODE courses
were the main driver of the intervention costs (54%).
Complete 2-year medication data of 500 patients
(90%) in the RECODE group and 478 patients (90%)
in the usual care group were extracted from the EMRs.
More than 85% of the participants used medication for
obstructive airway diseases in the 2-year trial period
(table 3).
Of the 1086 patients, 93% had complete healthcare
utilisation data at 6 months, 79% at 9 months, 88% at
12 months, 73% at 18 months and 75% at 24 months.
This was similar for both groups. The unit costs,
observed mean use of resources and associated costs, as
reported by the patients, are presented in table 3.
In both groups, important cost drivers were hospital
admissions, home care and productivity loss. Excluding
intervention costs, the adjusted mean total 2-year costs
(estimated from the generalised linear mixed model)
were significantly higher in the RECODE group than in
the usual care group by €584 from the healthcare per-
spective and €645 from the societal perspective (table 4).
Outcomes
Over a 2-year period, the number of QALYs was 0.04
(p=0.02) lower in the RECODE group than in the usual
care group while there was no significant difference in
the percentage of patients with an MCID on the CCQ,
nor in any of the other outcomes (table 4).
Cost-effectiveness
From a healthcare and societal perspective, the point
estimates of costs and effects pointed towards higher
costs and lower effects of the RECODE programme,
resulting in negative ICERs for all outcome measures
(QALYs, exacerbation avoided, additional patient with
an MCID on the CCQ score, and additional patient
with an MCID on the SGRQ score). The CE planes
of the different outcomes showed that the majority of
the bootstrap replications (>98%) had higher costs.
Furthermore, more than half of the bootstrap replica-
tions fell within the north-west quadrant of the plane
indicating that RECODE was dominated by the usual
care group, for example, more costs and less effects.
Sensitivity analyses
When including the intervention costs, the cost differ-
ence, which favoured usual care, further increased to a
Table 1 Baseline characteristics
RECODE
(n=554)
Usual care
(n=532)
Age (years), mean (SD) 68.2±11.3 68.4±11.1
Male sex (%) 50.5 57.3*
Employment (%) 27.7 28.8
Low education/low social
economic status (%)
39.2 41.5
Marital status: single (%) 37.0 38.3
FEV1% predicted, mean (SD) 67.7 (20.3) 67.9 (20.5)
Current smoker (%) 34.8 38.7
Former smoker (%) 53.8 52.6
Moderate exacerbation in the
past year, mean (SD)
0.36 (0.83) 0.33 (0.78)
Severe exacerbation in the
past 3 months, mean (SD)
0.02 (0.18) 0.02 (0.17)
Charlson comorbidity index 2.35 (1.26) 2.32 (1.27)
Major cardiovascular
disease (%)
14.6 17.7
Hypertension (%) 35.4 38.3
Diabetes (%) 14.6 14.8
Depression (%) 9.8 10.1
MRC score, mean (SD) 2.06 (1.30) 1.95 (1.26)
MRC score >2 (%) 35.1 31.6
CCQ score, mean (SD) 1.54 (0.98) 1.46 (0.96)
SGRQ total score, mean (SD) 36.7 (21.1) 34.5 (19.8)
EQ-5D score, mean (SD) 0.74 (0.25) 0.73 (0.28)
*Significant (p<0.05).
FEV1, forced expiratory volume in 1 s; MRC, Medical Research
Council; CCQ, Clinical COPD Questionnaire; SGRQ, St. George’s
Respiratory Questionnaire;EQ-5D, EuroQoL-5D.
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difference of €883 from the healthcare perspective and
€1005 from the societal perspective (see online supple-
mentary appendix 2).
Using a 12-month instead of a 24-month time horizon,
the costs per patient were significantly higher in the
RECODE group in comparison with the usual care group
by €408 from the healthcare perspective and €370 from
the societal perspective (see online supplementary
appendix 3). After 12 months, there was no significant
difference in QALYs, or any of the other outcomes,
except for the percentage of patients improving at least
the MCID on the CCQ, which was 7% less in the
RECODE group than in the usual care group. After
12 months, the costs per QALY ratio of RECODE
compared to usual care was €38 471 from a healthcare
perspective and €42 458 from a societal perspective.
The probability that RECODE is cost-effective at a willing-
ness-to-pay of €20 000 and €80 000 per QALY at
12 months was 8% and 79%, respectively (see online
supplementary appendix 4). From a societal perspective,
these probabilities were slightly higher, that is, 15%
and 81%.
Subgroup analyses
Only age showed a significant interaction with the effect
of RECODE on costs (see online supplementary appen-
dix 5 and 6). The difference in costs (healthcare and
societal perspective) between RECODE and usual care
was significantly lower in patients younger than 65 years
than in patients above 65 years. There was also a
significant interaction between age and the effect of
RECODE in terms of QALYs. In patients below 65, there
was no significant difference in QALYs between
RECODE and usual care, whereas in patients 65 or over
there were fewer QALYs in RECODE than in usual care
(see online supplementary appendix 4). It is more likely
that RECODE is cost-effective within the subgroup of
patients <65 years.
DISCUSSION
This study compared the costs and health effects of a
COPD-DM programme in primary care (RECODE) with
usual care in the Netherlands. Our results show that
RECODE is not cost-effective from a healthcare as well
as a societal perspective. The point estimates of costs
and effects pointed towards higher costs and no signifi-
cant difference in effects, except for 0.04 less QALYs.
The majority of bootstrap replications in the CE planes
showed that RECODE was dominated by usual care. The
decrease in utility, especially in the second year, might
be explained by the consistent pattern of no effect or a
worse effect on the outcomes. The reduction in utility
might also result from the increased awareness by
patients of their health problems as an effect of being
enrolled in the RECODE programme.
These unexpected findings cannot be related to weak-
nesses in the research design. The strength of our study
lies in the inclusion of a large and representative
group of patients with COPD recruited in primary care.
Table 2 Intervention costs (in €, 2013)
DM intervention cost description
Percentage of teams
with any use of
Mean cost per
team±SD (€)
Mean cost per
patient±SD (€)
RECODE Course
Catering 100 119±56 4.78±2.45
Location 100 3±4 0.15±0.21
Presenters 100 84±37 50.9±36.31
Other costs* 100 1174±587 3.63±2.39
Labour costs of replacement course participants 100 4008±1683 163.72±87.65
Travel 100 48±30 1.94±1.24
Refresher course
Catering 70 29±25 1.1±0.97
Location 70 – –
Presenters 70 146±123 5.94±6.63
Other costs* 70 – –
Labour costs attendees 70 273±273 10.84±11.69
Travel 70 7±6 0.25±0.23
ICT system ZORGDRAAD
Labour costs of ICT use 50 42±86 1.45±2.65
Labour costs of ICT support 100 1354±0 57.80±24.07
Monitoring reports
Labour costs of feedback report at baseline 100 333±141 13.56±6.2
Labour costs of feedback report at 6 months 100 67±28 2.71±1.24
Labour costs of feedback report at 12 months 100 133±57 5.42±2.48
Total 7862±2543 324±156
*Other costs include material and equipment used during the course.
DM, disease management; ICT, information and communications technologies.
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To avoid contamination, randomisation was performed
at the cluster level. Since blinding of participants and
clinicians was impossible, blinded research nurses col-
lected the data, while patients were instructed not to
report back on their type of intervention. Additional
strengths of this study are the 2-year follow-up period,
the broad range of health outcomes and cost categories
included and the sophisticated analyses that took into
account the hierarchical nature of the data. A limitation
of our study is that we collected healthcare resource util-
isation at baseline and at 6, 12, 18 and 24 months using a
questionnaire with a 3-month recall period, necessitating
the extrapolation of the 3-month data to 6 months to
estimate the costs of months 3–6, 15–18 and 21–24. We
chose to collect intermittent data for two reasons. The
first was to avoid study dropouts resulting from endless
questionnaires or daily diaries over a long follow-up
period. The second reason was that evidence from the
literature suggests that intermittent data provide reliable
estimates of total annual health expenditures.23 A second
limitation is that patients who dropped out were
significantly older and had a significantly worse baseline
score on the CCQ, SGRQ, MRC-dyspnoea and EQ-5D,
thus potentially jeopardising the generalisability of the
results. However, baseline characteristics of the dropouts
in the RECODE group and the dropouts in the usual
care group were not significantly different. Moreover,
after correction for baseline scores, no evidence of
benefits of the intervention were found, indicating that
dropouts are unlikely to have biased the results.
There are several possible explanations for the finding
that the RECODE intervention was not cost-effective.
First, it may be due to the relatively low intensity of our
pragmatic intervention. The RECODE programme did
not require the teams to implement all elements of
effective COPD-DM that they learnt during the courses.
Instead, each team made their own plan to redesign the
care process and implement COPD-DM. Consequently,
the mixture and intensity of interventions for individual
patients was dependent on the health status, personal
needs and preferences of the individual patients, as well
as on the specific focus that a team may have chosen,
Table 3 Unit costs, data sources, mean use of resources and associated costs over the 2 years, as reported by the patients
(unadjusted)
Unit
cost (€) Source*
RECODE Usual care
Any
use (%)
Mean
use
Mean
cost±SD (€)
Any
use (%)
Mean
use
Mean
cost±SD (€)
Costs from a healthcare perspective
GP, (home) visits, phone
contacts
15–46 a 91 16.23 476±504 89 14.02 401±450
Practice nurse, visits 23 b 74 5.51 131±277 75 5.18 109±166
Specialist, visits 78 a 78 10.05 784±1037 78 9.84 768±973
Emergency department, visits 163 a 26 0.78 127±284 23 0.79 129±346
Physiotherapist, visits 39 a 53 25.82 1007±1770 45 16.33 637±1260
Dietician, visits 29 a 21 1.45 42±141 19 1.21 35±148
Podiatrist, visits 32 b 43 3.78 121±203 40 3.27 105±167
Speech therapist, visits 36 a 3 0.12 4±42 2 0.28 10±158
Occupational therapy, visits 24 a 4 0.29 7±76 3 0.32 8±83
Rehabilitation centre, visits 78 a 12 3.86 459±2157 12 3.01 358±1731
Home care, hours of household
help
26 a 22 34.42 895±2287 20 31.01 806±2171
Home care, hours of personal
care
47 a 9 8.28 389±1995 8 9.49 446±2327
Home care, hours of nursing 70 a 6 2.11 148±1108 6 2.39 167±1064
Home care, other, hours 48 a 1 0.47 22±262 2 0.65 31±309
Hospital stay, days 493 a 25 4.65 2293±5915 25 4.84 2388±7522
Intensive care unit, days 2356 a 5 0.49 1161±11 316 2 0.14 328±2658
Drugs for obstructive airway
diseases
– c 84 – 945±814 84 – 934±1024
Other medication – c 91 – 1367±3421 90 – 1131±2506
Costs from a societal perspective
Travel expenses, public
transport/car, km
0.22 a 94 189.00 42±56 92 174.43 38±59
Productivity loss, absenteeism
hours
31–43 a 11 47.74 1698±8344 11 42.89 1649±8448
Productivity loss, presenteeism
hours
31–43 8 10.38 376±2304 9 10.92 374±1774
*Sources of unit costs used in the analysis: (1) Dutch guidelines for pharmacoeconomic research,9 (2) The Dutch Healthcare Authority NZA
(3) GIP Databank.20
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the level of implementation of the DM interventions
and the context within which each team operates. As an
example of an area that may not have been sufficiently
addressed during the courses, we should mention inter-
ventions to improve psychological health.28 However,
only 10% of the patients in the RECODE trial suffered
from a depression at baseline. Although this has prob-
ably influenced their motivation to change their health
behaviour and may have increased unscheduled care,29
it is unlikely to be a major explanation for the lack of
effect. Obviously, further research is required to under-
stand the conditions for a successful implementation
and thus cost-effectiveness of a COPD-DM programme.
Second, it is questionable whether the pragmatic
provider-oriented interventions of the RECODE pro-
gramme (eg, training and education, support in writing
practice reform plans, ICT system Zorgdraad) were opti-
mally translated into patient-oriented interventions. This
is important because it has been shown that successful
COPD-DM programmes mainly include patient-oriented
interventions.2 3 The literature showed that exercise is
an important success factor of a COPD-DM programme3
and that education, exercise and relaxation are import-
ant factors for reducing the use of urgent and unsched-
uled healthcare among people with COPD.30 In our
study, physical exercise was not mandatory and only
patients with MRC>2 received full reimbursement of
physiotherapy.
Third, there was limited room for improvement in
comparison with previous studies due to the relatively
high standard of COPD care in the Netherlands31 and
the low proportion of patients with severe COPD in this
study.2 3 It could be that a programme like RECODE
would have led to more positive results in settings where
the COPD care is less advanced. For instance, in 2005,
when the standards of good COPD care in developed
countries were less well developed, a Spanish study did
find that a community-based integrated care programme
in frail patients with COPD improved clinical outcomes
including survival and decreased the emergency depart-
ment visits.32 Moreover, Bourbeau et al33 34 demon-
strated positive results of a COPD-DM programme in
patients recruited from seven hospitals in Canada in
1999, while a similar programme in 15 general practices
in the Netherlands in 200631 found no long-term bene-
fits and a study in the USA in 2009 did even find nega-
tive results in patients recruited from 20 hospital-based
outpatient clinics.35 It might well be that as time passes
and the quality of COPD care improves, there is less
room for improvement. However, even in the presence
of incentivised quality improvement programmes like
the Quality and Outcome Framework in England, hos-
pital admissions for COPD still occur more frequently
among the least well served such as those in deprived
areas.36 So there is still room for improvement among
certain subgroups of patients with COPD and it might
be a question of targeting DM programmes at those
most likely to benefit.
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Fourth, changes in healthcare occurred during the
study period that affected COPD care in the RECODE
as well as the usual care group. Since July 2010, a new
bundled payment scheme for patients with COPD has
been introduced in the Netherlands to stimulate the
integration of care.37 In this scheme, healthcare insurers
purchase integrated care from care groups by negotiat-
ing a fixed price per patient per year for all multidiscip-
linary COPD care required by a patient. As the bundle
excludes secondary care and medications, it primarily sti-
mulates the cooperation between different providers in
the primary care setting. This increased attention for
integrated chronic care and the ability to reimburse
COPD interventions such as smoking cessation and
nutritional counselling could have stimulated integrated
care in the usual care group too.
Future research should determine the cost-
effectiveness of more intensive COPD-DM programmes
in primary care using a long(er) time horizon. Hence,
the gains from preventing patients with moderate COPD
to progress to severe COPD are likely to be detected
only in the long run.
In conclusion, this comprehensive economic evalu-
ation of an integrated care programme in primary care
showed that the programme increased costs but did not
improve health outcomes. It even reduced QALYs. This
is most likely due to the suboptimal translation of the
provider-oriented interventions of the RECODE pro-
gramme into patient-oriented interventions, the subopti-
mal implementation of the interventions, the relatively
mild COPD population and the national reforms in
COPD care.
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